Novo Nordisk shares fell over 6% as second-quarter sales for its weight-loss drug Wegovy missed investor expectations. Despite the decline, the company raised its full-year guidance and reported a 7% growth in adjusted sales driven by its obesity and diabetes franchises. Other financial updates included raised outlooks from Realty Income and Orion, alongside significant sales growth reported by Once Upon A Farm.
